Edition:
United States

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

22.75USD
16 Feb 2018
Change (% chg)

$0.54 (+2.43%)
Prev Close
$22.21
Open
$22.11
Day's High
$22.87
Day's Low
$22.11
Volume
127,852
Avg. Vol
98,119
52-wk High
$26.43
52-wk Low
$15.57

Latest Key Developments (Source: Significant Developments)

Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Retrophin Inc ::RETROPHIN PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK.‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​.‍COMPANY EXPECTS NET PRODUCT SALES FOR Q4 OF 2017 TO BE APPROXIMATELY $42 MILLION​.‍COMPANY EXPECTS A NEW DRUG APPLICATION FILING IN 2018 FOR ITS NEW FORMULATION OF THIOLA FOR TREATMENT OF CYSTINURIA.  Full Article

Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma
Friday, 5 Jan 2018 09:05am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING.RETROPHIN SAYS IF CO EXERCISES OPTION TO BUY CENSA, COMPANY WILL HAVE TO PAY $65 MILLION IN UPFRONT CONSIDERATION.RETROPHIN - ‍AGREED TO FUND CERTAIN DEVELOPMENT ACTIVITIES OF CENSA'S CNSA-001 PROGRAM IN AMOUNT EXPECTED TO BE ABOUT $16 MILLION THROUGH PROOF OF CONCEPT​.RETROPHIN - ALSO ‍HAS RIGHT TO ACQUIRE CENSA ON TERMS AND SUBJECT TO CONDITIONS SET FORTH IN A SEPARATE AGREEMENT AND PLAN OF MERGER​.  Full Article

Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Retrophin Inc ::RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU).RETROPHIN INC - ‍UNDER DEAL TERMS , CO IS MAKING A $10 MILLION UPFRONT PAYMENT TO CENSA AND WILL PROVIDE FUNDING FOR DEVELOPMENT OF CNSA-001 IN PKU​.RETROPHIN - UNDER DEAL TERMS, ‍CENSA WILL RUN DEVELOPMENT PROGRAM FOR CNSA-001​, WHICH WILL BE CONDUCTED UNDER OVERSIGHT OF A JOINT STEERING COMMITTEE.  Full Article

Retrophin reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:21pm EST 

Nov 7 (Reuters) - Retrophin Inc :Retrophin reports third quarter 2017 financial results.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.46.Q3 adjusted non-GAAP earnings per share $0.15.  Full Article

Retrophin reports Q2 loss per share $0.34
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Retrophin Inc :Retrophin reports second quarter 2017 financial results.Q2 loss per share $0.34.Q2 revenue $39 million versus I/B/E/S view $37.4 million.Q2 adjusted non-gaap earnings per share $0.03.Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Protocol design for pivotal phase 3 trial of sparsentan in fsgs complete.Retrophin Inc - company reiterates its full-year 2017 guidance of $150.0 to $160.0 million in net product sales.  Full Article

Retrophin commences patient dosing in international, registrational phase 3 trial of RE-024 in PKAN
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Retrophin Inc :Retrophin commences patient dosing in international, registrational phase 3 trial of re-024 in pkan.Retrophin inc -announced that first patient has been dosed in fort study registrational phase 3 clinical trial assessing safety and efficacy of re-024.  Full Article

Retrophin Q1 loss per share $0.29
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Retrophin Inc ::Retrophin reports first quarter 2017 financial results.Q1 loss per share $0.29.Q1 revenue $34 million versus I/B/E/S view $36.2 million.Q1 adjusted non-gaap earnings per share $0.01.Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Retrophin Inc says company reiterates its full-year 2017 guidance of $150.0 to $160.0 million in net product sales.Fy2017 revenue view $155.8 million -- Thomson Reuters I/B/E/S.  Full Article

Retrophin initiates a plan to consolidate its operations to its corporate headquarters in San Diego
Wednesday, 8 Mar 2017 05:17pm EST 

Retrophin Inc : On March 7, 2017, company initiated a plan to consolidate its operations to its corporate headquarters in San Diego, CA . Intends to close its Cambridge, MA office by end of 2017 . As part of plan, select employees will relocate from Cambridge, MA to San Diego headquarters by end of 2017-SEC filing . Estimates it could incur up to $4.5 million in employee related separation and transitional cash charges as a result of the consolidation .As part of plan, replacements for other functions will be hired during course of 2017.  Full Article

Retrophin Q4 loss per share $0.23
Wednesday, 1 Mar 2017 04:01pm EST 

Retrophin Inc : Retrophin inc says phase 3 trial of sparsentan in fsgs to initiate in second half of 2017 . Retrophin inc - phase 3 trial of sparsentan in fsgs to initiate in second half of 2017 . Retrophin inc - interim analysis of proteinuria to serve as basis for nda filing for accelerated approval . Retrophin inc - net product sales for q4 of 2016 were $37.3 million, compared to net product sales of $30.4 million for same period in 2015 . Retrophin inc - company expects full year 2017 net product sales to be in range of $150.0 to $160.0 million . Retrophin provides sparsentan regulatory update; reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.23 . Q4 adjusted non-gaap earnings per share $0.00 .Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Retrophin reports Q3 loss per share $1.00
Thursday, 3 Nov 2016 04:01pm EDT 

Retrophin Inc : Trial evaluating efficacy of re-024 in pantothenate kinase-associated neurodegeneration remains on track to initiate before year-end 2016 . Net product sales for q3 of 2016 were $33.9 million, compared to $28.0 million for same period in 2015 . Q3 earnings per share view $0.38, revenue view $34.8 million -- Thomson Reuters I/B/E/S . Retrophin reports third quarter 2016 financial results . Q3 adjusted non-gaap loss per share $0.09 . Q3 loss per share $1.00 .Q3 revenue rose 21 percent.  Full Article

BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018

* ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​